{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:41:56Z","timestamp":1792698116583,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-07599-7","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:48:06Z","timestamp":1738439286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer\u2019s disease by administration through an intranasal route"],"prefix":"10.1038","volume":"8","author":[{"given":"Anne-Claire","family":"Groo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Curel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6023-1861","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Malzert-Fr\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"S\u00e9guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7857-1642","authenticated-orcid":false,"given":"Oph\u00e9lie","family":"Bento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Corvaisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Culerier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00eblle","family":"Callizot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Culley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-5518","authenticated-orcid":false,"given":"Sylvie","family":"Claeysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-2082","authenticated-orcid":false,"given":"Christophe","family":"Rochais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-615X","authenticated-orcid":false,"given":"Patrick","family":"Dallemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"7599_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alz Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alz Dis."},{"key":"7599_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"J. R Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"7599_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-022-00292-3","volume":"11","author":"C Song","year":"2022","unstructured":"Song, C. et al. Immunotherapy for Alzheimer\u2019s disease: targeting \u03b2-amyloid and beyond. Transl. Neurodegener. 11, 1\u201317 (2022).","journal-title":"Transl. Neurodegener."},{"key":"7599_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/brain\/awad005","volume":"146","author":"R Perneczky","year":"2023","unstructured":"Perneczky, R. et al. Anti-amyloid antibody therapies in Alzheimer\u2019s disease. Brain 146, 842\u2013849 (2023).","journal-title":"Brain"},{"key":"7599_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0609-7","volume":"27","author":"L. K Huang","year":"2020","unstructured":"Huang, L. K. et al. Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci. 27, 1\u201319 (2020).","journal-title":"J. Biomed. Sci."},{"key":"7599_CR6","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/S1353-8020(13)70032-4","volume":"20S1","author":"M. B. H Youdim","year":"2014","unstructured":"Youdim, M. B. H. et al. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20S1, S132\u2013S136 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"7599_CR7","doi-asserted-by":"publisher","first-page":"E3825","DOI":"10.1073\/pnas.1410315111","volume":"111","author":"C Lecoutey","year":"2014","unstructured":"Lecoutey, C. et al. Design of donecopride, a dual serotonin subtype 4 receptor agonist\/acetylcholinesterase inhibitor with potential interest for Alzheimer\u2019s disease treatment. Proc. Natl. Acad. Sci. USA 111, E3825\u2013E3830 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"7599_CR8","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1021\/acs.jmedchem.5b00115","volume":"58","author":"C Rochais","year":"2015","unstructured":"Rochais, C. et al. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer\u2019s disease: the design of donecopride. J. Med. Chem. 58, 3172\u20133187 (2015).","journal-title":"J. Med. Chem."},{"key":"7599_CR9","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/bph.14964","volume":"177","author":"C Rochais","year":"2020","unstructured":"Rochais, C. et al. Donecopride, a Swiss army knife with potential against Alzheimer\u2019s disease. Br. J. Pharm. 177, 1988\u20132005 (2020).","journal-title":"Br. J. Pharm."},{"key":"7599_CR10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/jphp.13273","volume":"72","author":"J Jourdan","year":"2020","unstructured":"Jourdan, J. et al. Drug repositioning: a brief overview. J. Pharm. Pharm. 72, 1145\u20131151 (2020).","journal-title":"J. Pharm. Pharm."},{"key":"7599_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12295","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings, J. et al. Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimer\u2019s. Dement 8, e12295 (2022).","journal-title":"Alzheimer\u2019s. Dement"},{"key":"7599_CR12","first-page":"1","volume":"8","author":"A Kumar","year":"2018","unstructured":"Kumar, A. et al. Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer\u2019s disease. Sci. Rep. 8, 1\u201312 (2018).","journal-title":"Sci. Rep."},{"key":"7599_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1192\/bjp.2017.21","volume":"212","author":"N Eady","year":"2018","unstructured":"Eady, N. et al. Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: Clinical cohort study. Br. J. Psychiatry 212, 155\u2013160 (2018).","journal-title":"Br. J. Psychiatry"},{"key":"7599_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2015.00220","volume":"9","author":"M Gannon","year":"2015","unstructured":"Gannon, M. et al. Noradrenergic dysfunction in Alzheimer\u2019s disease. Front Neurosci. 9, 1\u201312 (2015).","journal-title":"Front Neurosci."},{"key":"7599_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/jnc.15782","volume":"165","author":"S Li","year":"2023","unstructured":"Li, S. The \u03b2-adrenergic hypothesis of synaptic and microglial impairment in Alzheimer\u2019s disease. J. Neurochem 165, 289\u2013302 (2023).","journal-title":"J. Neurochem"},{"key":"7599_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/1531-8249(199901)45:1<82::AID-ART14>3.0.CO;2-T","volume":"45","author":"W. J. G Hoogendijk","year":"1999","unstructured":"Hoogendijk, W. J. G. et al. Increased activity of surviving locus ceruleus neurons in Alzheimer\u2019s disease. Ann. Neurol. 45, 82\u201391 (1999).","journal-title":"Ann. Neurol."},{"key":"7599_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/bmj.282.6258.93","volume":"282","author":"A. J Cross","year":"1981","unstructured":"Cross, A. J. et al. Reduced dopamine-beta-hydroxylase activity in Alzheimer\u2019s disease. Br. Med J. 282, 93\u201394 (1981).","journal-title":"Br. Med J."},{"key":"7599_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.neuint.2010.03.001","volume":"56","author":"B Guly\u00e1s","year":"2010","unstructured":"Guly\u00e1s, B. et al. The norepinephrine transporter (NET) radioligand (S,S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer\u2019s disease: A post-mortem autoradiographic study. Neurochem. Int. 56, 789\u2013798 (2010).","journal-title":"Neurochem. Int."},{"key":"7599_CR19","doi-asserted-by":"publisher","first-page":"7ra17","DOI":"10.1126\/scitranslmed.3000258","volume":"1","author":"A Salehi","year":"2009","unstructured":"Salehi, A. et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 1, 7ra17 (2009).","journal-title":"Sci. Transl. Med."},{"key":"7599_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/1567205012666150921095924","volume":"13","author":"C Phillips","year":"2016","unstructured":"Phillips, C. et al. Noradrenergic system in Down syndrome and Alzheimer\u2019s disease a target for therapy. Curr. Alzheimer Res 13, 68\u201383 (2016).","journal-title":"Curr. Alzheimer Res"},{"key":"7599_CR21","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.neurobiolaging.2007.12.004","volume":"30","author":"Q Wang","year":"2009","unstructured":"Wang, Q. et al. Inhibition of LTP by beta-amyloid is prevented by activation of \u03b22 adrenoceptors and stimulation of the cAMP\/PKA signalling pathway. Neurobiol. Aging 30, 1608\u20131613 (2009).","journal-title":"Neurobiol. Aging"},{"key":"7599_CR22","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nprot.2010.72","volume":"5","author":"A Jan","year":"2010","unstructured":"Jan, A. et al. Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer\u2019s disease research. Nat. Protoc. 5, 1186\u20131209 (2010).","journal-title":"Nat. Protoc."},{"key":"7599_CR23","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1742-4658.2010.07568.x","volume":"277","author":"M Sakono","year":"2010","unstructured":"Sakono, M. & Zako, T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 277, 1348\u20131358 (2010).","journal-title":"FEBS J."},{"key":"7599_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.681532","volume":"12","author":"N Callizot","year":"2021","unstructured":"Callizot, N. et al. Huperzia serrata Extract \u2018NSP01\u2019 With Neuroprotective Effects-Potential Synergies of Huperzine A and Polyphenols. Front Pharm. 12, 681532 (2021). Aug 30.","journal-title":"Front Pharm."},{"key":"7599_CR25","doi-asserted-by":"publisher","first-page":"23871","DOI":"10.1074\/jbc.272.38.23871","volume":"272","author":"B January","year":"1997","unstructured":"January, B. et al. \u03b22-Adrenergic Receptor Desensitization, Internalization, and Phosphorylation in Response to Full and Partial Agonists. J. Biol. Chem. 272, 23871\u201323879 (1997).","journal-title":"J. Biol. Chem."},{"key":"7599_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/sj.bjp.0705050","volume":"138","author":"L. K Chong","year":"2003","unstructured":"Chong, L. K. et al. Desensitization of \u03b22-adrenoceptor-mediated responses by short-acting \u03b22-adrenoceptor agonists in human lung mast cells. Br. J. Pharm. 138, 512\u2013520 (2003).","journal-title":"Br. J. Pharm."},{"key":"7599_CR27","doi-asserted-by":"publisher","unstructured":"Adnet, T. et al. Pharmacotechnical development of a nasal drug delivery composite nanosystem intended for alzheimer\u2019s disease treatment. Pharmaceutics 12. https:\/\/doi.org\/10.3390\/pharmaceutics12030251 (2020).","DOI":"10.3390\/pharmaceutics12030251"},{"key":"7599_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/jnc.14345","volume":"146","author":"B Calvo-Flores Guzm\u00e1n","year":"2018","unstructured":"Calvo-Flores Guzm\u00e1n, B. et al. The GABAergic system as a therapeutic target for Alzheimer\u2019s disease. J. Neurochem. 146, 649\u2013669 (2018).","journal-title":"J. Neurochem."},{"key":"7599_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/molecules25030693","volume":"25","author":"B Calvo-Flores Guzm\u00e1n","year":"2020","unstructured":"Calvo-Flores Guzm\u00e1n, B. et al. Amyloid-Beta1-42 induced increase in GABAergic tonic conductance in mouse hippocampal CA1 pyramidal cells. Molecules 25, 693 (2020).","journal-title":"Molecules"},{"key":"7599_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","volume":"463","author":"L Prut","year":"2003","unstructured":"Prut, L. et al. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharm. 463, 3\u201333 (2003).","journal-title":"Eur. J. Pharm."},{"key":"7599_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/297681a0","volume":"297","author":"R. G Morris","year":"1982","unstructured":"Morris, R. G. et al. Place navigation impaired in rats with hippocampal lesions. Nature 297, 681\u2013683 (1982).","journal-title":"Nature"},{"key":"7599_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0165-0270(84)90007-4","volume":"11","author":"R. G Morris","year":"1984","unstructured":"Morris, R. G. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47\u201360 (1984).","journal-title":"J. Neurosci. Methods"},{"key":"7599_CR33","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1177\/1352458514528758","volume":"20","author":"C. P Tsai","year":"2014","unstructured":"Tsai, C. P. et al. Beta2- adrenergic agonist use and the risk of multiple sclerosis: A total population-based case-control study. Mult. Scler. 20, 1593\u20131601 (2014).","journal-title":"Mult. Scler."},{"key":"7599_CR34","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/mds.108","volume":"33","author":"N Gronich","year":"2018","unstructured":"Gronich, N. et al. beta2- adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease. Mov. Disord. 33, 1465\u20131471 (2018).","journal-title":"Mov. Disord."},{"key":"7599_CR35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal, S. et al. beta2- adrenoreceptor is a regulator of the alpha- synuclein gene driving risk of Parkinson\u2019s disease. Science 357, 891\u2013898 (2017).","journal-title":"Science"},{"key":"7599_CR36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3233\/JAD-215057","volume":"87","author":"D. R Hutten","year":"2022","unstructured":"Hutten, D. R. et al. Targeting the Beta- 2- adrenergic receptor and the risk of developing Alzheimer\u2019s disease: a retrospective inception cohort study. J. Alzheimer\u2019s. Dis. 87, 1089\u20131101 (2022).","journal-title":"J. Alzheimer\u2019s. Dis."},{"key":"7599_CR37","first-page":"155","volume":"57","author":"S. A Cojocariu","year":"2021","unstructured":"Cojocariu, S. A. et al. Neuropsychiatric consequences of lipophilic Beta-blockers. Med. (Kaunas.) 57, 155 (2021).","journal-title":"Med. (Kaunas.)"},{"key":"7599_CR38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jamainternmed.2016.7701","volume":"177","author":"M. A Steinman","year":"2017","unstructured":"Steinman, M. A. et al. Association of beta- blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction. JAMA Intern. Med. 177, 254\u2013262 (2017).","journal-title":"JAMA Intern. Med."},{"key":"7599_CR39","unstructured":"Rochais, C. et al. Bambuterol for the treatment of Alzheimer\u2019s disease WO\/2019\/202400. PCT\/IB2019\/000523 (2019)."},{"key":"7599_CR40","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/jnr.23193","volume":"91","author":"N Callizot","year":"2013","unstructured":"Callizot, N. et al. Operational dissection of \u03b2-amyloid cytopathic effects on cultured neurons. J. Neurosci. Res. 91, 706\u2013716 (2013).","journal-title":"J. Neurosci. Res."},{"key":"7599_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116615","volume":"275","author":"M Drop","year":"2024","unstructured":"Drop, M. et al. 5-HT6 receptor neutral antagonists protect astrocytes: A lesson from 2-phenylpyrrole derivatives. Eur. J. Med. Chem. 275, 116615 (2024).","journal-title":"Eur. J. Med. Chem."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07599-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:48:11Z","timestamp":1738439291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07599-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7599"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-07599-7","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N Callizot is co-founder of Neuro-Sys, member of the scientific board and consulting for: Alzprotect, Inflectis, Axoltis, Raya Therapeutics, Neuralia. R Legrand, C Rochais and P Dallemagne are co-founders and members of the scientific board of RonomA-Pharma. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}